风险因素对未接种疫苗的风湿病患者COVID-19结局的影响:基于COVID-19全球风湿病联盟登记处的不同大流行时期比较分析
研究纳入2020年3月至2022年6月COVID-19全球风湿病联盟登记处中19256例未接种疫苗的风湿病合并COVID-19患者,采用序数logistic回归分析不同大流行时期与重症COVID-19相关的风险因素。结果显示,年龄较大、男性、合并症较多、使用糖皮质激素、疾病活动度较高或居住在低人类发展指数地区的患者在各时期结局均较差;不同风湿病类型中特定药物与结局的关联存在差异。结论认为未接种疫苗风湿病患者的重症风险因素在各流行时期相似,仍需包括疫苗接种在内的持续努力。
要点
- 年龄较大、男性、合并症多、使用糖皮质激素、疾病活动度高及低人类发展指数地区与未接种疫苗风湿病患者更差COVID-19结局相关。
- 类风湿关节炎患者中,柳氮磺吡啶和B细胞清除治疗与更差结局相关,肿瘤坏死因子抑制剂与改善结局相关。
- 结缔组织病或血管炎患者中,B细胞清除治疗与更差结局相关。
核心结论
- 未接种疫苗的风湿病患者中,重症COVID-19结局的风险因素在不同大流行时期相似。
- 仍需包括疫苗接种在内的持续努力以降低该人群COVID-19严重程度,尤其是本研究中识别出的具有医学和社会脆弱性的患者。
研究设计与样本
- 基于COVID-19全球风湿病联盟登记处的比较分析,纳入2020年3月至2022年6月登记的风湿病合并COVID-19患者。
- 主要分析纳入所有未接种疫苗患者并跨COVID-19大流行时期,采用序数logistic回归模型(未住院、住院、死亡),协变量包括COVID-19诊断日期、年龄、性别、种族和/或民族、合并症、风湿病活动度、药物及人类发展指数。
- 亚分析按风湿病类型对患者进行分层。
主要发现
- 共纳入19256例未接种疫苗的风湿病合并COVID-19患者。
- 年龄较大、男性、合并症较多、使用糖皮质激素、疾病活动度较高或居住在低人类发展指数地区的患者在各时期结局均较差。
- 类风湿关节炎患者中,柳氮磺吡啶和B细胞清除治疗与更差结局相关,肿瘤坏死因子抑制剂与改善结局相关。
- 结缔组织病或血管炎患者中,B细胞清除治疗与更差结局相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Approximately one third of individuals worldwide have not received a COVID-19 vaccine. Although studies have investigated risk factors linked to severe COVID-19 among unvaccinated people with rheumatic diseases (RDs), we know less about whether these factors changed as the pandemic progressed. We aimed to identify risk factors associated with severe COVID-19 in unvaccinated individuals in different pandemic epochs corresponding to major variants of concern. METHODS: Patients with RDs and COVID-19 were entered into the COVID-19 Global Rheumatology Alliance Registry between March 2020 and June 2022. An ordinal logistic regression model (not hospitalized, hospitalized, and death) was used with date of COVID-19 diagnosis, age, sex, race and/or ethnicity, comorbidities, RD activity, medications, and the human development index (HDI) as covariates. The main analysis included all unvaccinated patients across COVID-19 pandemic epochs; subanalyses stratified patients according to RD types. RESULTS: Among 19,256 unvaccinated people with RDs and COVID-19, those who were older, male, had more comorbidities, used glucocorticoids, had higher disease activity, or lived in lower HDI regions had worse outcomes across epochs. For those with rheumatoid arthritis, sulfasalazine and B-cell-depleting therapy were associated with worse outcomes, and tumor necrosis factor inhibitors were associated with improved outcomes. In those with connective tissue disease or vasculitis, B-cell-depleting therapy was associated with worse outcomes. CONCLUSION: Risk factors for severe COVID-19 outcomes were similar throughout pandemic epochs in unvaccinated people with RDs. Ongoing efforts, including vaccination, are needed to reduce COVID-19 severity in this population, particularly in those with medical and social vulnerabilities identified in this study.
引用
- Yazdany J, Ware A, Wallace ZS, et al. Impact of Risk Factors on COVID-19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID-19 Global Rheumatology Alliance Registry. Arthritis Care Res (Hoboken). 2023. PMID: 37643903. doi:10.1002/acr.25220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。